Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (472)	10/12/1998 7:55:00 PM
From: Marty	Read Replies (1) \| Respond to of 857

This looks like an arm wrestling contest, back and forth, between Asensio and Carter. Asensio has a reputation and a following but that is about it. Carter has a lot more muscle represented by medical credentials and medical studies. I also think there is more money available on the long side with more and more individuals and institutions learning about the drug's potential and increasing their holdings the closer it gets to full approval time. The shorts are typically very panicky and could easily quickly run up the stock a lot by themselves once price starts up on any positive announcement from ongoing studies, the FDA, or published reports. It looks Asensio is grasping at straws now by publishing such nonsense. He made a very bad bet going up against Carter.